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Lipoprotein(a) stimulates growth of human mesangial cells and lesions [1, 2], suggesting that they represent related phe-
induces activation of phospholipase C via pertussis toxin-sensi- nomena. This hypothesis has been supported by animal
tive G proteins. studies in which lipid-lowering treatment slowed the pro-Background. Renal disease is commonly associated with hy-
gression of glomerulosclerosis [3, 4]. Lipoprotein(a) [Lp(a)]perlipidemia and correlates with glomerular accumulation of
is a low-density lipoprotein (LDL)-like lipoprotein withatherogenic lipoproteins, for example, lipoprotein(a) [Lp(a)],
and mesangial hypercellularity. Specific binding of Lp(a) to apoprotein(a) [apo(a)]. Apo(a) is highly homologous to
mesangial cells and induction of c-myc and c-fos expression has plasminogen with a large size variation from 420 to 840
been demonstrated. Therefore, in this study, we investigated a
kDa. The plasma levels of Lp(a) in healthy individualspossible growth stimulatory effect and mode of action of Lp(a)
mainly depend on the genetically determined apo(a) phe-in human mesangial cells.
Methods. Lp(a) was purified from the regenerate fluid of a notype [5]. The distribution of the apo(a) isoforms in
dextran sulfate column-based low-density lipoprotein aphere- patients with end-stage renal disease treated with hemo-
sis system. Human mesangial cells were isolated by a sequential dialysis (HD) or chronic ambulatory peritoneal dialysissieving technique from patients undergoing tumor nephrectomy.
(CAPD) is not different from the healthy population butDNA synthesis was measured by [3H]-thymidine incorporation.
is phenotype specific. Levels of Lp(a) were significantlyThe intracellular calcium concentration ([Ca21]i) was deter-
mined by Fura 2-fluorescence, and inositol 1,4,5-trisphosphate elevated only in patients with the high molecular weight
(1,4,5-IP3) concentration was measured by a radioreceptor assay. isoform [6]. A decreased renal Lp(a) metabolism [7],
Results. The data show that Lp(a) bound to the cells with
induction of Lp(a) synthesis by the liver because of uri-a Kd of 17.0 mg/ml and increased DNA synthesis and cell prolif-
nary protein loss in nephrotic syndrome [8–11], or perito-eration. Lp(a) caused a rapid increase in 1,4,5-IP3 and [Ca21]i
via a pertussis toxin-sensitive mechanism. The phospholipase neal protein loss in CAPD [12] may be the reasons for
C (PLC) inhibitor U73122 abolished Lp(a)-induced cell prolif- the elevated Lp(a) levels in these patients.
eration. In contrast, vasopressin-induced increase in 1,4,5-IP3 Apo(a) and apo B, constituents of Lp(a), have beenand [Ca21]i was pertussis toxin insensitive.
found to be colocalized in glomeruli from patients withConclusion. This study revealed that Lp(a) stimulates growth
chronic renal disease [13]. Therefore, it has been pro-of human mesangial cells. Lp(a)-induced signaling involves bind-
ing to a receptor and stimulation of PLC via Gi proteins. Stimu- posed that elevated plasma levels of Lp(a) may contrib-
lation of PLC appears to be essential for the growth stimulatory ute toward the progression of renal disease. However,effect of Lp(a). Whether these effects of Lp(a) contribute to
direct evidence for a role of Lp(a) in the progression ofthe pathophysiology of renal disease needs to be determined.
renal disease has not yet been provided [14]. In vitro
experiments showed an interaction of Lp(a) with mesan-
gial cells such as binding and uptake of Lp(a) by humanBiochemical and histological features of glomerulo-
mesangial cells [15]. Lp(a) has been shown to stimulatesclerosis are similar to those found in systemic vascular
proliferation and expression of c-myc and c-fos in rat
mesangial cells [16]. Proliferation of mesangial cells con-Key words: cell signaling, inositol phosphates, hyperlipidemia, glomer-
ulosclerosis, end-stage renal disease. tributes to the progression of glomerulosclerosis [17].
Thus, Lp(a) may modulate the progression of renal dis-Received for publication November 7, 1997
ease. A growth stimulatory effect of Lp(a) has not beenand in revised form November 3, 1998
Accepted for publication November 3, 1998 demonstrated in human mesangial cells, and the initial
events of Lp(a) signaling have not yet been characterized. 1999 by the International Society of Nephrology
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In this study, we investigated the mode of action of Iodination of lipoprotein(a)
Lp(a) in human mesangial cells. The data show that Lp(a) Lipoprotein(a) was radioiodinated according to the
binds specifically to human mesangial cells and stimulates method of McFarlane [19], with modifications of Bil-
proliferation by increasing inositol 1,4,5-trisphosphate heimer, Eisenberg and Levy [20]. The specific activity
(1,4,5-IP3) production and the intracellular calcium con- following precipitation of [125I]Lp(a) with trichloroacetic
acid was between 100 and 120 cpm/ng protein. [125I]Lp(a)centration ([Ca21]i) via pertussis toxin-sensitive G pro-
was stored at 48C and was used within two weeks.teins.
Cell culture
METHODS Human mesangial cells were isolated by a sequential
sieving technique from patients undergoing tumor nephrec-Materials
tomy. All experiments were performed from passages 3Lipoprotein-deficient serum (LPDS), affinity-purified
to 6. Mesangial cell cultures were identified by morpho-horseradish peroxidase-conjugated anti-mouse and anti-
logical and immunologic characteristics such as positive
rabbit immunoglobulin G, pertussis toxin, NAD1, and soy- staining for actin and negative staining for factor VIII
bean trypsin inhibitor were obtained from Sigma Chemi- and cytokeratin. To exclude fibroblast contamination, cells
cal Co. (Vienna, Austria). Enhanced chemiluminescence were grown for two weeks in L-valine–deficient RPMI
reagents and films were obtained from Amersham Inc. 1640 supplemented with 10% FCS, 10 mm N-2-hydroxy-
(Braunschweig, Germany). The phospholipase C (PLC) ethylpiperazine-N9-2-ethanesulfonic acid (HEPES), pH
inhibitor U73122 and ionomycin were from Calbiochem 7.4, 1 mm Na pyruvate, 100 U/ml penicillin/streptomycin.
(La Jolla, CA, USA). [32P]NAD1 and the 1,4,5-IP3 assay Culture media were replaced three times per week.
were from DuPont-New England Nuclear (Bad Hom-
Binding of [125I]Lp(a) to human mesangial cellsburg, Germany). Fura 2 acetoxymethyl ester was from
Molecular Probes (Eugene, OR, USA). RPMI 1640 me- Cell culture tests were performed as described by
Goldstein et al for the binding of [125I]LDL with somedium and fetal calf serum (FCS) were from Life Technol-
modifications [21]. In brief, human mesangial cells wereogies (Gaithersburg, MD, USA). Polyvinylidene diflu-
grown in 24-well culture dishes (20,000 cells per well) andoride transfer membranes were from Millipore (Bedford,
were used at 70 to 90% confluence. To induce maximalMA, USA).
receptor activity, human mesangial cells were incubated
in RMPI 1640 medium containing 10% LPDS for 48Isolation of lipoprotein(a)
hours. Then the medium was replaced by fresh LPDS-Lipoprotein(a) was purified from the regenerate fluid
containing medium, and [125I]-labeled Lp(a) was added
of a dextran sulfate column-based low density lipopro- for one hour at 48C. Thereafter, culture dishes were
tein (LDL) apheresis system (Kanekafuchi MA 01– washed three times with ice-cold binding buffer (150 mm
Liposorber LA 15) as described [18]. The regenerate NaCl, 50 mm Tris-HCl, pH 7.4) including bovine serum
fluid was centrifuged at 44,000 r.p.m. for 24 hours at albumin (BSA; 2 mg/ml; wt/vol) and four times with
158C in a Beckman Ti 50.2 rotor, first at a density of binding buffer lacking BSA. Nonspecific binding was
1.125 kg/liter and then at 1.050 kg/liter at 44,000 r.p.m. measured with 20-fold excess of unlabeled Lp(a). Non-
for 22 hours. The Lp(a)-containing fraction was chro- linear regression analysis was used to quantitate the
matographed on Bio-Gel A.15 m (200 to 400 mesh, equil- binding properties of Lp(a) to the cells.
ibrated with 50 mm Tris-HCl, pH 7.4, 200 mm NaCl, 25
Measurement of DNA synthesis bymm ethylenediaminetetraacetic acid, 20 U/liter of aproti-
[3H]thymidine incorporationnin, 1 mg/liter NaN3, column length 100 cm). Lp(a) sub-
Mesangial cells were plated on 96-well plates (3000fractions were free of LDL as determined by 2 to 5%
cells per well) and grown to subconfluency. Prior to thenative gradient gel electrophoresis and did not contain
experiments, cells were incubated for 48 hours in cellother proteins, as determined by sodium dodecyl sulfate
culture medium with or without 0.5% FCS. Incubationpolyacrylamide gel electrophoresis (SDS-PAGE) on 4
was continued for another 24 hours with variable concen-
to 15% gradient gels. Apo(a) phenotypes were deter- trations of Lp(a) and 1 mCi [3H]thymidine/ml. Subse-
mined by SDS-PAGE using homogenous gels (T 5 5%) quently, the cells were trypsinated, washed, and har-
and commercial apo(a) phenotyping standard (Immuno vested onto filter paper. Radioactivity on the filters was
Diagnostika, Vienna, Germany) as the reference. The determined by liquid scintillation counting.
nomenclature of Utermann et al was used [5]. Lp(a)
Measurement of cell proliferationused in all experiments was isolated from a single donor
with a S2/S4 isoform. Prior to use, Lp(a) was extensively Proliferation of mesangial cells was measured by de-
termination of the number of viable cells. A colorimetricdialyzed against phosphate-buffered saline.
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assay (Promega, Madison, WI, USA) was used in which sisted of (in mm) the following: 250 sucrose, 0.1 MgSO4,
0.2 phenylmethylsulfonyl fluoride, 50 HEPES, pH 7.0, 5a tetrazolium salt is bioreduced by viable cells to aqueous
soluble formazan. The quantity of formazan product as mg/ml leupeptin, 5 mg/ml aprotinin, and 0.01% (wt/vol)
soybean trypsin inhibitor. The homogenate was cen-measured by the absorbance at 490 nm was directly pro-
portional to the number of living cells. The protocol was trifuged at 150 3 g for 10 minutes at 48C followed by
27,000 3 g for 25 minutes at 48C. The resultant pelletthe same as for DNA synthesis with the indicated Lp(a)
concentration. was resuspended in homogenization buffer and stored
in aliquots in liquid nitrogen.
Measurement of the intracellular
calcium concentration Adenosine diphosphate ribosylation of Gia
To verify pertussis toxin-catalyzed adenosine diphos-Mesangial cells were plated on 6 cm Petri dishes in
RPMI 1640 and grown to subconfluent monolayers. Cells phate (ADP) ribosylation of Gia, cells were incubated
for 12 hours with or without pertussis toxin (200 ng/ml).were loaded with the Ca21-sensitive dye Fura 2 acetoxy-
methyl ester (1 mm) for 20 minutes in Krebs-Henseleit- Then cell membranes were isolated as described earlier
here. Membranes were incubated at 378C for 20 minutesHepes buffer containing (in mm): 135 NaCl, 5 KCl, 2
Na2HPO4, 0.5 MgSO4, 10 glucose, 10 HEPES, pH 7.4, in a medium containing 20 mm Tris-HCl (pH 7.0), 1 mm
ethylenediaminetetraacetic acid (EDTA), 10 mm thymi-0.025% (wt/vol) albumin (fatty acid free), and 1 CaCl2.
[Ca21]i was measured by dual wavelength excitation with dine, 50 mm nicotinamide adenine dinucleotide phos-
phate (NADP1), 1 mm nicotinamide adenine dinucleotidea Zeiss Axioplan microscope. Dual excitation, alternat-
ing between 340 and 380 nm, was provided by a Spex (NAD1), 2 mg/ml pertussis toxin [activated by preincuba-
tion with 20 mm dithiothreitol and 1 mm adenosine tri-fluorolog system (Spex Industries, Edison, NJ, USA),
and emission at 505 nm associated with this excitation phosphate (ATP) for 30 min at 328C], 0.05% (wt/vol)
Lubrol PX, and 2 mCi [32P]NAD1 in a final volume ofwas stored and analyzed by DM3000 cm software (Spex).
Calibration of fluorescent signals was accomplished by 50 ml. Five microliter aliquots were subjected to SDS-
PAGE. Proteins were transferred to polyvinylideneemploying the equation of Grynkiewicz et al ([Ca21]i 5
Kd 3 (F 2 Fmin/Fmax 2 F); Kd 5 224 nm) [22]. At the difluoride (PVDF) membranes for autoradiography.
end of each experiment, the maximum fluorescence was
Miscellaneousdetected after the addition of the calcium ionophore
ionomycin (15 mm) followed by recording minimal fluo- Protein was measured according to the method of
Bradford using BSA as a standard [24]. All experimentsrescence with egtazic acid (EGTA; 7.5 mm). To investi-
gate the contribution of extracellular Ca21, additional were repeated at least three times. The data presented
are means 6 sd. Statistical significance was calculatedexperiments were performed in nominally calcium-free
solution with a low concentration of EGTA (10 mm) to using Student’s t-test for paired values.
chelate contaminating calcium.
RESULTSMeasurement of inositol
1,4,5-trisphosphate production Binding of lipoprotein(a) to human mesangial cells
[125I]Lp(a) binding to human mesangial cells showedCells were subcultivated on 6 cm dishes and were grown
to subconfluence. The medium was changed 12 hours the typical characteristics of a saturable receptor-medi-
ated uptake (Fig. 1). With nonlinear regression, analysisprior to the experiments to serum-free medium. 1,4,5-IP3
was measured by displacement of bound 1,4,5-[3H]IP3 revealed a Kd of 17.0 6 5.9 mg/ml and a maximum binding
capacity of 1014.6 6 139.0 ng/mg protein. Thus, the affin-using a radioreceptor assay. Cells were incubated for
specified times and were mixed with an equal amount ity and capacity of Lp(a) binding to the mesangial cells
were similar to previously published data for Lp(a) andof ice-cold trichloroacetic acid (20%). Following centri-
fugation at 5000 3 g and 48C, supernatants were extracted LDL in human mesangial cells [15].
with 1,1,2-trichloro-1,2,2-triflouroethane/trioctylamine (3:1
Effect of lipoprotein(a) on DNA synthesis andvol/vol). The 1,4,5-IP3 content of the samples was deter-
cell proliferationmined according to the assay protocol provided by the
manufacturer. DNA synthesis was measured by [3H]thymidine up-
take during 24-hour incubation with and without 0.5%
Isolation of mesangial cell membranes FCS. As illustrated in Figure 2A, Lp(a) caused an in-
crease in DNA synthesis under serum-free conditions.Mesangial cell membranes were isolated as previously
described for pancreas acini with minor modifications [23]. Lp(a)-induced DNA synthesis was significant at an Lp(a)
concentration of 5 mg/ml. In the presence of 0.5% FCS,In brief, mesangial cells were homogenized by 20 strokes
using a glass Teflon potter. Homogenization medium con- Lp(a) did not influence DNA synthesis, indicating that
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Effect of lipoprotein(a) on inositol
1,4,5-trisphosphate production
Lipoprotein(a) at 50 mg/ml triggered a rapid increase
in the 1,4,5-IP3 concentration. A maximum increase in
1,4,5-IP3 of 0.66 pmol/mg protein (basal value of 0.29 6
0.09 pmol/mg protein) was observed five seconds after
addition of Lp(a), followed by a decline on continuation
of the incubation (Fig. 4). Thus, it appears that Lp(a)
increased [Ca21]i via increase in 1,4,5-IP3 production.
Effect of pertussis toxin on intracellular calcium
concentration and inositol 1,4,5-trisphosphate
production in response to lipoprotein(a)
and vasopressin
Fig. 1. Concentration-dependent binding of [125I]Lp(a) by human mes- To investigate whether Lp(a)-induced increases in
angial cells. Unspecific binding was determined at 48C and was sub- [Ca21]i and 1,4,5-IP3 involve activation of pertussis toxin-tracted. Data are given as means 6 sd. Measurements were carried out
sensitive G proteins (Gi/o proteins), mesangial cells werein quadruplicate. Kd 5 17.0 mg protein/ml. Bmax 5 1014.6 ng/mg protein.
treated for three hours with pertussis toxin (200 ng/ml)
prior to measurement of Lp(a)-induced increases in
[Ca21]i and 1,4,5-IP3. The effect of pertussis toxin treat-FCS blunted the effect of Lp(a) on DNA synthesis. The
ment was verified in homogenates from pertussis toxin-level of DNA synthesis was significantly higher in the
treated and control cells. A second pertussis toxin-cata-presence of 0.5% FCS.
lyzed ADP ribosylation in the presence of [32P] NAD1Cell proliferation was measured by a viability assay.
showed that pertussis toxin pretreatment reduced incor-Similar to the effect of Lp(a) on [3H]thymidine incorpo-
poration of radioactivity into Gia by approximately 80%.ration, Lp(a) had a proliferative effect in the absence of
As shown in Figures 4 and 5, pertussis toxin pretreatmentFCS (Fig. 2B). Maximum increase was observed at a
of the cells abolished Lp(a) (50 mg/ml)-induced increaseLp(a) concentration of 10 mg/ml (137.6 6 15.1%,
of [Ca21]i and 1,4,5-IP3 level, whereas the vasopressincontrol 5 100%, P , 0.01). In the presence of 0.5%
(100 nm)-induced [Ca21]i response remained unchanged.FCS, Lp(a) had no effect.
Thus, it appears that the Lp(a)-induced, but not theIn the presence of the PLC inhibitor U73122 (1 mm),
vasopressin-induced, activation of phosphoinositide-spe-Lp(a) did not stimulate DNA synthesis and cell prolifera-
cific PLC involves activation of pertussis toxin-sensitivetion (Fig. 2).
G proteins.
Effect of lipoprotein(a) on the intracellular free
calcium concentration
DISCUSSION
To elucidate possible signal transduction pathways of
Elevated plasma levels of Lp(a) are a common featureLp(a), we measured the [Ca21]i in single Fura 2-loaded
in renal disease and ESRD and have been suggested asmesangial cells grown on coverslips. As shown in Figure
an important risk factor for accelerated atherosclerosis3A, low concentrations of Lp(a) (5 mg/ml) caused a small
[25, 26] and progressive loss of renal function [10]. How-transient increase in [Ca21]i, whereas a high concentra-
ever, a role of Lp(a) in the pathogenesis of renal diseasetion of Lp(a) (50 mg/ml) elicited a stronger and more
has not been proven [14]. The underlying mechanismsrapid transient calcium increase (Fig. 3B). In the pres-
that result in elevated Lp(a) plasma levels are heteroge-ence of 1 mm extracellular Ca21, the peak [Ca21]i was
neous. Among HD and CAPD patients, a more pro-382.0 6 122.2 nm. In a nominally calcium-free solution
nounced increase in the plasma Lp(a) level was found insupplemented with 10 mm EGTA to chelate contaminat-
those patients expressing predominantly high molecularing Ca21, the peak [Ca21]i was reduced to 242.9 6 62.1 nm
weight isoforms of apo(a) [6]. In patients with nephrotic(Fig. 3 C, D), suggesting that the Lp(a)-induced calcium
syndrome or CAPD, protein loss in the urine or perito-transients are mainly due to calcium release from intra-
neum may induce hepatic synthesis of Lp(a) [8–12]. Incellular pools. When the extracellular [Ca21] was reduced
HD patients, the underlying mechanism of Lp(a) elevationto less than 100 nm by the addition of 10 mm EGTA,
is less evident. In these patients, the phenotype-specificthe Lp(a)-induced peak [Ca21]i was reduced to 135 6
elevated Lp(a) levels are decreased by kidney transplanta-15.1 nm (data not shown). Thus, high concentrations of
tion [27], which might be attributable to a decreasedEGTA abolished the calcium transient, presumably by
chelation of intracellular calcium. metabolism of Lp(a) in renal failure [7]. Other mecha-
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Fig. 2. Effect of lipoprotein(a) [Lp(a)] on [3H]thymidine uptake (A) and tetrazolium uptake (B). Cells were incubated in the presence of 0.5%
FCS (h) and the absence of FCS (fetal calf serum; ) and in the presence of the PLC (phospholipase C) inhibitor U73122 (1 mm) without FCS
(j). Data are given as means 6 sd of 12 independent experiments. Asterisks indicate a significant increase as compared with the control experiments
(*P , 0.001).
Fig. 3. Effect of Lp(a) on intracellular calcium concentration ([Ca21]i) in Fura 2-loaded single human mesangial cells. Human mesangial cells
grown on coverslips were loaded with Fura 2-AM for 30 minutes at 378C and were washed twice with Krebs-Henseleit-Hepes buffer immediately
before the experiment. Lp(a) was added to the incubation medium containing 1 mm Ca21 [A, Lp(a) 5 mg/ml; B, Lp(a) 50 mg/ml]. The influence
of the extracellular calcium concentration is illustrated in (C) [1 5 addition of 50 mg/ml Lp(a)] and (D). The experiments shown in (A–C) are
representative for 10 independent experiments. Data shown in panel D are means 6 sd.
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Fig. 4. Effect of Lp(a) and pertussis toxin on Lp(a)-induced inositol
1,4,5-triphosphate (1,4,5-IP3) production. Mesangial cells were incu-
bated with (s) or without (r) pertussis toxin (0.2 mg/ml) for 12 hours
and were stimulated with Lp(a) (50 mg/ml) at 378C for the indicated
time. The amount of 1,4,5-IP3 was determined as described in Methods
section. Data are expressed as the means of three independent experi- Fig. 5. Effect of pertussis toxin on [Ca21]i variation in response to
ments. The asterisk indicates a significant increase as compared to the Lp(a) and vasopressin. Human mesangial cells were cells grown on
initial value (*P , 0.001). coverslips and were preincubated with pertussis toxin (0.2 mg/ml) for
12 hours. Cells were loaded with Fura 2-AM for 30 minutes at 378C
and were washed twice with Krebs-Henseleit-Hepes buffer immediately
before the experiment. Lp(a) (50 mg/ml) and vasopressin (100 nm) were
added to the cells. Fura 2 fluorescence of individual cells was monitored
nisms contributing to increased plasma levels of Lp(a) at room temperature. The experiment shown is representative for four
independent observations.could be malnutrition and/or chronic inflammation [28].
Attempts to elucidate through which pathophysiologi-
cal mechanism lipoproteins may contribute to renal func-
tion loss have been made in cell culture studies. Binding trations. Other lipoproteins such as very low density
studies have been performed to investigate the interac- lipoprotein (VLDL), high-density lipoprotein (HDL),
tion of lipoproteins with different cell types [29–31]. Al- and lysolecithin may also exhibit growth regulatory func-
though specific binding sites could be demonstrated, it tion in mesangial cells [35, 36]. Furthermore, LDL was
is not clear whether Lp(a) binds to the LDL receptor or found to increase [3H]thymidine incorporation in smooth
to a yet uncharacterized receptor. Because of the similarity muscle cells and to potentiate platelet-derived growth
of LDL and Lp(a), it has been speculated that Lp(a) factor AA-induced proliferation [37]. In vitro prolifera-
may also bind to the LDL receptor. Studies carried out tion of mesangial cells is inhibited by hydroxymethyl
in fibroblasts, HepG2 cells, and macrophages support glutaryl CoA-reductase inhibitors [38]. These “hormone-
the concept that Lp(a) and LDL bind to the same receptor like” effects suggest that phospholipoproteins activate
[32, 33]. However, patients expressing little or no LDL specific intracellular signaling pathways. Several studies
receptor activity showed a normal catabolism of Lp(a), have shown that LDL and HDL induce activation of
suggesting different binding sites for Lp(a) and LDL PLC and increase [Ca21]i [39, 40]. We show here for the
[34]. Similar to an earlier study, binding of Lp(a) to first time that this pathway is also activated by Lp(a) in
human and rat mesangial cells showed typical features of human mesangial cells, as exposure of cells to Lp(a)
a receptor-mediated process, that is, Michaelis-Menten resulted in a rapid formation of 1,4,5-IP3 and an increase
kinetics and saturability [15, 16]. The differences in the of [Ca21]i. In experiments using solutions without added
calculated Kd and Vmax values might be due to differences calcium and a low concentration of EGTA, Lp(a)-induced
in cell passages and/or differences of the Lp(a) isoforms. calcium peak was moderately reduced. This indicates
The latter may be of particular interest because epidemi- that the Lp(a)-induced Ca21 transients are mainly de-
ological studies in patients with atherosclerosis indicate rived from intracellular pools. Furthermore, because the
variable atherogeneity of the different Lp(a) isoforms. PLC inhibitor U73122 abolished Lp(a)-induced cell pro-
The effect of Lp(a) on cell proliferation depended on liferation, activation of PLC appears to be crucial for the
the incubation protocol. If the incubation was carried growth stimulatory effect of Lp(a). In addition, our results
out in the presence of 0.5% FCS, Lp(a) had no effect indicate the involvement of pertussis toxin-sensitive G
on cell proliferation. However, when the experiments proteins (Gi/o) in Lp(a)-induced increase in 1,4,5-IP3 and
were performed in the absence of FCS, Lp(a) induced [Ca21]i, because the formation of 1,4,5-IP3 and subse-
a significant increase in cell proliferation and DNA syn- quent increase of [Ca21]i could be suppressed by pretreat-
thesis. The effects of Lp(a) on DNA synthesis and prolif- ment of the cells with pertussis toxin. Evidence suggests
eration in our experiments were different from that of that pertussis toxin-sensitive activation of PLC is medi-
LDL [29], which showed a biphasic dose–response curve ated by receptor activation of Gi/o proteins, dissociation
of G protein a subunit from Gbg, and Gbg-mediatedwith proliferation at low and inhibition at high concen-
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plasma concentrations suggest removal of Lp[a] from the renalactivation of PLC-b isoenzymes [41]. Gbg is capable of
circulation. J Lipid Res 38:1755–1763, 1997
activating PLC-b2 and PLC-b3 and, to a smaller extent, 8. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thil-
let J: Elevated lipoprotein(a) levels in primary nephrotic syn-PLC-b1. Mesangial cells express PLC-b1 and PLC-b3, but
drome. Am J Kidney Dis 22:808–813, 1993not PLC-b2 (unpublished results). Thus, because PLC-b3
9. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead
is more potently activated by Gbg than PLC-b1, it ap- JF: Lipoprotein(a) in patients with proteinuria. Nephrol Dial
Transplant 7:597–601, 1992pears reasonable to assume that Lp(a) activates PLC-b3
10. Wanner C, Rader D, Bartens W, Kra¨mer J, Brewer HB, Schol-rather than PLC-b1. In agreement with previous results
meyer P, Wieland H: Elevated plasma lipoprotein (a) in patients
[42], vasopressin-induced increases in 1,4,5-IP3 and [Ca21]i with nephrotic syndrome. Ann Intern Med 119:263–269, 1993
11. Stenvinkel P, Berglund L, Heimbu¨rger O, Pettersen E, Alve-were not sensitive to pertussis toxin, suggesting that vaso-
strand A: Lipoprotein (a) in nephrotic syndrome. Kidney Intpressin activates PLC-b1 and/or PLC-b3 via Gq/11. Fur- 44:1116–1123, 1993
ther experiments are necessary to show which of these 12. Heimbu¨rger O, Stenvinkel P, Berglund L, Traneus A, Lind-
holm B: Increased plasma lipoprotein (a) in continuous ambulatoryG protein and PLC isoforms are activated by receptor
peritoneal dialysis is related to peritoneal transport of protein andagonists in mesangial cells.
glucose. Nephron 72:135–144, 1996
In conclusion, our study showed that Lp(a) induces 13. Sato H, Suzuki S, Ueno M, Shimada H, Kaeasawa R, Nishi S,
Arakawa M: Localisation of apolipoprotein(a) and B-100 in vari-proliferation of human mesangial cells by stimulation of
ous renal disease. Kidney Int 43:430–435, 1993PLC and mobilization of intracellular calcium via pertus-
14. Samuelsson O, Attman P-O, Khight-Gibson C, Larsson R, Mu-
sis toxin-sensitive G proteins. Whether or not these ef- lec H, Wedel H, Weiss L, Alaupovic P: Plasma levels of lipopro-
tein(a) do not predict progression of human chronic renal failure.fects contribute to the pathophysiology of renal disease
Nephrol Dial Transplant 11:2237–2243, 1996needs to be determined.
15. Kramer-Guth A, Greiber S, Pavenstadt H, Quaschning T,
Winkler K, Schollmeyer P, Wanner C: Interaction of native and
oxidized lipoprotein(a) with human mesangial cells and matrix.
APPENDIX Kidney Int 49:1250–1261, 1996
16. Greiber S, Kramer-Guth A, Pavenstadt H, Gutenkunst M,Abbreviations used in this article are: ADP, adenosine diphosphate;
Schollmeyer P, Wanner C: Effects of lipoprotein(a) on mesangialapo(a), apoprotein (a); ATP, adenosine triphosphate; BSA, bovine
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